ZCP
TRVI icon

Z3 Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

Z3 Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$732K Sell
39,250
-300
-0.8% -$4.36K 0.15% 99
2026
Q1 		$472K Buy
39,550
+100
+0.3% +$1.12K 0.12% 118
2025
Q4 		$494K Buy
+39,450
New +$456K 0.12% 116

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Z3 Capital Partners's TRVI Position: Q2 2026 in Review

Z3 Capital Partners reduced its Trevi Therapeutics (TRVI) stake by 0.76% in Q2 2026, selling an estimated $4.36K and leaving 39,250 shares worth $732K. The position accounts for 0.15% of the portfolio, ranked #99.

Z3 Capital Partners first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Z3 Capital Partners held 39,250 shares of Trevi Therapeutics worth $732K as of Q2 2026.
  • Z3 Capital Partners sold 300 Trevi Therapeutics shares in Q2 2026, an estimated $4.36K.
  • Trevi Therapeutics made up 0.15% of Z3 Capital Partners's portfolio in Q2 2026, its #99 holding.
  • Z3 Capital Partners first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.